3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Sarcoma
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
43
venetoclax
30
Cytarabine
25
fludarabine
22
fludarabine phosphate
17
Azacitidine
16
Mycophenolic Acid
13
Whole-Body Irradiation
12
Dexamethasone
12
ruxolitinib
11
Rituximab
11
Busulfan
11
Vincristine
10
Methotrexate
10
Etoposide
10
Tacrolimus
9
Mercaptopurine
9
Daunorubicin
9
Prednisone
8
Filgrastim
8
Dasatinib
8
ibrutinib
7
Peripheral Blood Stem Cell Transplantation
7
Melphalan
7
Granulocyte Colony-Stimulating Factor
7
Doxorubicin
7
Decitabine
7
pegaspargase
6
blinatumomab
6
Mesna
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia
×
Interleukin-15
×
1 year
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled